Alentis Therapeutics

Executive Summary

Alentis Therapeutics is a clinical-stage biotechnology company pioneering therapies targeting Claudin-1 (CLDN1), a transmembrane protein overexpressed in numerous cancers and fibrotic diseases. The company's proprietary platform generates antibody-drug conjugates (ADCs) and monoclonal antibodies designed to selectively bind CLDN1, enabling tumor cell killing and reversal of fibrosis. Alentis' lead ADC candidate has demonstrated potent antitumor activity in preclinical models, with a favorable safety profile, and is now advancing into Phase 1 clinical trials for CLDN1-positive solid tumors. The company also has pipeline assets for fibrotic indications, including non-alcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis, leveraging CLDN-1's role in tissue scarring. Alentis has attracted significant investor attention due to the broad therapeutic potential of CLDN1 and its differentiated mechanism of action. The company's near-term focus is on generating initial clinical proof-of-concept data. Key upcoming milestones include the first-in-human Phase 1 trial results for lead ADC in advanced solid tumors, expected in late 2026, which will provide critical safety and early efficacy signals. Additionally, Alentis is likely to file an Investigational New Drug (IND) application for its fibrosis antibody in mid-2026, expanding its pipeline into non-oncology indications. The company may also seek strategic partnerships to co-develop its fibrosis assets with a larger pharmaceutical partner. While Alentis is well-capitalized for its current development phase, success in early trials is essential to unlock additional value and de-risk the platform.

Upcoming Catalysts (preview)

• Q4 2026Phase 1 safety and efficacy data for lead ADC (CLDN1-directed)50% success
• Q3 2026IND filing for CLDN1 antibody in fibrosis indication60% success
• H2 2026Strategic partnership or licensing deal for fibrosis program40% success